In The News

    • JAN 25 2017

    Role of GPCRs for Oncology Highlighted in “Bioscience Technology”

    In 2016, we discovered that our lead molecule, ONC201, targets a GPCR known as dopamine receptor D2 (DRD2) and that our other molecules in development also target different GPCRs.   Although GPCRs are the most common target in modern medicine (30-50% of all drugs), GPCRs have not historically been targeted in oncology.  Recently, there has been

    • OCT 27 2016

    ONC201 in Clinical Trial of Triple-Negative Breast Cancer at University of Wisconsin

    The study, being conducted by Dr. Vince Cryns, will enroll 112 patients who will receive ONC201 in combination with either a normal or methionine restricted diet. Dr. Cryns has shown in preclinical studies that methionine restriction makes cells more susceptible to ONC201’s cancer killing effects. The full release from the University of Wisconsin can be

    • OCT 19 2016

    FDA Announces Orphan Grant Recipients, Including Oncoceutics

    The U.S. Food and Drug Administration today announced that it has awarded 21 new clinical trial research grants totaling more than $23 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry with research spanning domestic

    • OCT 06 2016

    Oncoceutics GPCR Discovery Partner DiscoverX Highlights Imipridone Class

    DiscoverX, a leader in GPCR profiling and screening services, recently highlighted imipridones, Oncoceutics’ proprietary class of small molecules, discussing their ability to target GPCRs, and the role that can play in developing cancer therapeutics. The article can be read here.